Paxlovid Adverse Reactions

Summary of the safety profile: The safety of Paxlovid is based on data from Study C4671005 (EPIC-HR), a Phase 2/3 randomised, placebo-controlled trial in non-hospitalised adult participants with a laboratory confirmed diagnosis of SARS-CoV-2 infection (see Pharmacology: Pharmacodynamics under Actions). A total of 2,224 symptomatic adult participants 18 years of age and older who are at high risk of developing severe COVID-19 illness received at least one dose of either Paxlovid (nirmatrelvir/ritonavir 300 mg/100 mg) (n=1,109) or placebo (n=1,115). Study drugs were to be taken twice daily for up to 5 days.
Adverse reactions in the Paxlovid group (≥1%) that occurred at a greater frequency than in the placebo group were dysgeusia (5.6% and 0.3%, respectively), diarrhoea (3.1% and 1.6%), vomiting (1.1% and 0.8%) and headache (1.4% and 1.3%).
Tabulated summary of adverse reactions: The adverse reactions in Table 8 are listed as follows by system organ class and frequency. Frequencies are defined as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); not known (frequency cannot be estimated from the available data). (See Table 8.)

Click on icon to see table/diagram/image

Paediatric population: The safety and efficacy of Paxlovid in paediatric patients have not been established.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.